Associated tags: Receptor (biochemistry), Complement, C5a, Inflammation, Autoimmunity, Pharmaceutical industry, Therapy, Patient, COVID-19, FDA
Locations: EUROPEAN UNION, EUA, ARDS, AUSTRALIA, MAD, PK, ET, JENA, DE, HIVES, NEW YORK CITY, GERMANY
I&I,
Research,
Patient,
Nephrology,
University of North Carolina,
Safety,
Hidradenitis suppurativa,
UAS7,
CSU,
University,
PRO,
Receptor (biochemistry),
Inflammation,
Therapy,
Medical school,
Hematology,
Calendar,
HS,
Biomarker,
Quality of life,
BID,
Neurology,
Pharmaceutical industry Supplemental information related to today’s event, including presentations conducted by the KOLs and InflaRx management can be found in the accompanying slide deck here .
Key Points:
- Supplemental information related to today’s event, including presentations conducted by the KOLs and InflaRx management can be found in the accompanying slide deck here .
- Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx has been eager to provide additional details of its development plans for INF904 and to further showcase the tremendous promise of our approach to C5aR inhibition, initially in CSU and HS, and more broadly in I&I.
- In the CSU group, patients in Study Arms 1 and 2 will be dosed with INF904 at 30 mg and 90 mg BID (twice daily), respectively.
- Given the potential of INF904 to have a broad commercial footprint, InflaRx believes INF904 could address meaningful markets in immuno-dermatology and in immuno-inflammation, including in nephrology, neurology and hematology.
Patient,
COVID-19,
IMV,
Food,
FDA,
Mortality,
Tocilizumab,
Conference,
American Thoracic Society,
MD,
Hospice and palliative medicine,
JAK,
Risk,
ATS,
Intensive care medicine,
Poster,
Safety,
Therapy,
Standard of care,
Pharmaceutical industry InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.
Key Points:
- InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.
- Tocilizumab, an anti-IL6R antibody, and baricitinib, a JAK inhibitor, are immunomodulators used in some patients as part of the standard of care treatment in this trial.
- Day 60 all-cause mortality was 16.4% and 49.3%, respectively (HR 0.25; 95% CI:0.09-0.68, p=0.006), a significant relative reduction.
- We believe this analysis further supports the life-saving potential of vilobelimab in the acute care setting and indicates our continued commitment to these patients.”
Retrieved on:
Wednesday, April 24, 2024
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.
Key Points:
- JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.
- InflaRx will participate in a panel titled, New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia scheduled on May 14, 2024, at 2:30 PM EDT / 8:30 PM CEST.
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.
Key Points:
- JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.
- The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.
- To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call.
- A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.
Retrieved on:
Thursday, February 22, 2024
Therapy,
Capital market,
Research,
CFA,
Proteomics,
Hematology,
Biomedicine,
Pyoderma,
Biomedical engineering,
Receptor (biochemistry),
Pharmaceutical industry JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.
Key Points:
- JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.
- Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.
- Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We are delighted to welcome Jan to our team.
- Jan joins InflaRx from Olink Proteomics where he was Vice President, Investor Relations & Capital Markets.
Retrieved on:
Thursday, January 25, 2024
ANN,
Death,
Mortality,
Patient,
The Lancet,
Intubation,
Hospital,
Intensive care medicine,
FCCP,
COVID-19 deaths,
Internal medicine,
Survival,
Medicine,
ECMO,
Critical care,
Food,
Commitment,
Disease,
COVID-19,
FDA,
Therapy,
IMV,
Extracorporeal membrane oxygenation,
Emergency Use Authorization,
Physician,
Pharmaceutical industry InflaRx is determined to support broader access to GOHIBIC for eligible patients.
Key Points:
- InflaRx is determined to support broader access to GOHIBIC for eligible patients.
- ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program).
- With today´s announcement, we are demonstrating our strong commitment to help make GOHIBIC available for the most affected COVID-19 patients as a potential life-saving therapy.
- For detailed information about the Commitment Program and to file a claim, please visit this link: The InflaRx Commitment Program .
Retrieved on:
Thursday, January 4, 2024
Receptor (biochemistry),
EST,
Conference,
C5a,
Aes,
Biotechnology,
BID,
Cmax,
MD,
Conference call,
PD,
Food,
SAD,
Patient,
Safety,
Therapy,
Atomic mass,
Pharmaceutical industry INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.
Key Points:
- INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.
- “We are very pleased that the MAD part of the Phase I study exceeded the already compelling results from the SAD part of the study.
- InflaRx currently plans to initiate a short-term dosing Phase II study towards the end of 2024, followed by a longer-term dosing Phase II study in 2025.
- A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.
FDA,
Arm,
Multinational,
Food,
Therapy,
PG,
Biotechnology,
MD,
European Medicines Agency,
Ulcer,
OD,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Clutch (eggs),
Phase,
EMA,
Phase III offensive,
Safety,
Patient,
Pyoderma,
Neutrophil,
Pharmaceutical industry “We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum.
Key Points:
- “We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum.
- In both arms, corticosteroid treatment will be initiated on day 1 and will be tapered off within the first 8 weeks of the trial.
- The primary endpoint of the study is complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment.
- The enrollment period is projected to last at least two years, and its overall period will depend on the total trial size after sample size adaptation.
